Catalent laying out $315M to snatch another gene therapy CDMO

Catalent, which carved out a place in gene therapies with its $1.2 billion Paragon Services deal, is adding another serving to its operations. It will pay $315 million for Masthercell Global, a Belgium-based cell and gene therapy CDMO with operations in Europe and the U.S.